- Trials with a EudraCT protocol (802)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (23)
802 result(s) found for: Releasing hormone.
Displaying page 1 of 41.
EudraCT Number: 2006-004764-31 | Sponsor Protocol Number: 02-2006 | Start Date*: 2007-01-11 |
Sponsor Name:Max Planck Institute of Psychiatry | ||
Full Title: Effects of corticotropin-releasing hormone on sleep electroencephalogram and sleep associated hormone secretion in young healthy women | ||
Medical condition: Healthy volunteers. The aim is to test the effects of CRH on sleep electroencephalogram and sleep associated secretion of growth hormone and cortisol | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000384-26 | Sponsor Protocol Number: BPLG-005 | Start Date*: 2005-11-10 | |||||||||||
Sponsor Name:LG Life Science Ltd. [...] | |||||||||||||
Full Title: A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency. | |||||||||||||
Medical condition: growth hormone deficiency in adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Ongoing) SE (Completed) CZ (Completed) GB (Completed) SK (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002892-16 | Sponsor Protocol Number: NN8640-4054 | Start Date*: 2014-10-07 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A multicentre, multinational, randomised, parallel-group, placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-00... | |||||||||||||
Medical condition: Growth hormone deficiency in adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DE (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005613-38 | Sponsor Protocol Number: 44648368 | Start Date*: 2006-05-31 |
Sponsor Name:Dr. Chris Thompson | ||
Full Title: Assessment of platelet function in the hypopituitary population. Does hormone replacement therapy alter thrombotic risk? | ||
Medical condition: Hypopituitarism refers to decreased secretion of pituitary hormones, which can result from diseases of the pituitary gland or from diseases of the hypothalamus, which cause diminished secretion of ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002125-42 | Sponsor Protocol Number: CTH9507J | Start Date*: 2004-09-22 |
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | ||
Full Title: EFFECT OF PROLONGED TREATMENT WITH TH9507 ON IGF-I LEVELS IN ADOLESCENTS WITH ISOLATED GH DEFICIENCY DUE TO HYPOTHALAMIC PATHOGENESIS | ||
Medical condition: EVALUATION OF GROWTH HORMONE RELEASE | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000929-42 | Sponsor Protocol Number: TCH-306 | Start Date*: 2021-06-09 | |||||||||||
Sponsor Name:Ascendis Pharma Endocrinology Division A/S | |||||||||||||
Full Title: foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin ... | |||||||||||||
Medical condition: Adult Growth Hormone Deficiency (AGHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SK (Completed) FR (Completed) DK (Prematurely Ended) BG (Completed) ES (Ongoing) NL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005080-10 | Sponsor Protocol Number: SHM001 | Start Date*: 2008-05-08 | |||||||||||
Sponsor Name:University Hospitals of Leicester NHS Trust | |||||||||||||
Full Title: Irregular vaginal bleeding with etonorgestrel contraceptive implant - A pilot randomised controlled trial of prophylactic down regulation with a Gonadotrophin releasing hormone analogue prior to im... | |||||||||||||
Medical condition: To investigate if a gonadotrophin releasing hormone (GnRH) analogue injection given to women one month before insertion of the contraceptive implant (Implanon®) reduces the common implant side effe... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002698-13 | Sponsor Protocol Number: GX-H9-002 | Start Date*: 2015-01-14 | |||||||||||
Sponsor Name:Genexine, Inc | |||||||||||||
Full Title: A randomized, active-controlled, multiple-dose, open-label study to evaluate the safety, tolerability, and efficacy of the long-acting antibody-fused recombinant human growth hormone (GX-H9) in adu... | |||||||||||||
Medical condition: Adult Growth Hormone Deficiency (AGHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) SE (Completed) DE (Completed) GR (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002072-24 | Sponsor Protocol Number: 15VR7 | Start Date*: 2015-10-22 | |||||||||||
Sponsor Name:Versartis Inc. | |||||||||||||
Full Title: An Open-Label, Dose Finding, International Phase 2 Study with Once Monthly Subcutaneous Somavaratan (VRS-317) in Adult Growth Hormone Deficiency (GHD) Versartis International Trial in Adults with ... | |||||||||||||
Medical condition: Growth Hormone Deficiency in adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001681-25 | Sponsor Protocol Number: 23681 | Start Date*: 2015-07-15 |
Sponsor Name:Merck KGaA | ||
Full Title: An Open, Multicenter, Randomized, Controlled Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Ex... | ||
Medical condition: Small for Gestational Age | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2007-003233-16 | Sponsor Protocol Number: TH9507-CTR-1012 | Start Date*: 2007-09-19 | |||||||||||
Sponsor Name:Theratechnologies Inc. | |||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Su... | |||||||||||||
Medical condition: HIV-associated lipodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) GB (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002471-11 | Sponsor Protocol Number: Leuprorelin-4002 | Start Date*: 2022-08-08 | |||||||||||
Sponsor Name:Takeda (China) International Trading Co., Ltd. | |||||||||||||
Full Title: An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP) | |||||||||||||
Medical condition: Central Precocious Puberty | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001269-10 | Sponsor Protocol Number: Doc-Pred | Start Date*: 2016-07-14 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: A pharmacokinetic study of Docetaxel and Prednisone in men with metastatic castration-resistant or hormone-sensitive prostate cancer. | ||
Medical condition: Metastatic prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000830-37 | Sponsor Protocol Number: CP-4-005 | Start Date*: 2013-07-03 | |||||||||||
Sponsor Name:OPKO Biologics Ltd. | |||||||||||||
Full Title: A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency | |||||||||||||
Medical condition: Adult or childhood onset growth hormone deficiency (GHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) GR (Completed) GB (Completed) AT (Completed) ES (Prematurely Ended) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000727-15 | Sponsor Protocol Number: 9238IL/0048 | Start Date*: 2004-12-03 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women with Hormone Receptor Positive A... | ||
Medical condition: Hormone receptor positive breast cancer with disease progression after prior non-steroidal aromatase inhibitor (AI) therapy | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005444-88 | Sponsor Protocol Number: TH9507-CTR-1011 | Start Date*: 2007-01-16 | |||||||||||
Sponsor Name:Theratechnologies Inc. | |||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess A... | |||||||||||||
Medical condition: HIV-associated lipodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) GB (Completed) DE (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003980-74 | Sponsor Protocol Number: BAY1007626/15731 | Start Date*: 2015-06-17 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Multi-center, randomized, comparator-controlled, single-blind, parallel-group study to investigate the pharmacodynamics, pharmacokinetics and safety of an intrauterine system releasing BAY 1007626,... | |||||||||||||
Medical condition: Contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) GB (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002963-31 | Sponsor Protocol Number: D-CN-52014-243 | Start Date*: 2023-01-13 |
Sponsor Name:Ipsen Pharma | ||
Full Title: AN OPEN-LABEL, MULTICENTRE, SINGLE-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF TRIPTORELIN 3-MONTH FORMULATION IN CHINESE CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY | ||
Medical condition: Central Precocious Puberty | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-001166-13 | Sponsor Protocol Number: COU-AA-001 | Start Date*: 2005-09-21 | |||||||||||
Sponsor Name:Cougar Biotechnology, Inc | |||||||||||||
Full Title: A Phase I/II Open Label Study of the 17α-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy | |||||||||||||
Medical condition: Hormone refractory prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020825-42 | Sponsor Protocol Number: RTOG0815 | Start Date*: 2010-11-08 | |||||||||||
Sponsor Name:Radiation Therapy Oncology Group | |||||||||||||
Full Title: A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER | |||||||||||||
Medical condition: intermediate risk prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
